Sleep apnea pill maker Apnimed files for US IPO as biotech market revives
Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering ​in the U.S. on Friday.
The Atomic take
Sleep apnea affects an estimated 900 million people globally, yet the standard treatment remains a bulky CPAP machine that many patients abandon within a year. Apnimed is betting that an oral drug, addressing the root muscle mechanics that collapse the airway during sleep, can capture the large share of sufferers who reject or cannot tolerate current options. Watch the pricing and demand for this IPO as an early read on whether public investors are ready to fund late-stage biotech again, and track Apnimed's Phase 3 data that will determine whether the pill actually reaches the market.
Read the full story at Reuters →Know where humanity is headed.
Five forces. One brief. Free, every Monday morning.
Get The Atomic Five